SMARCA4 and neoplasm: Jelinic et al. [58] sorted out the data and found that SMARCA4-regulated transcriptional programs might affect tumor immunogenicity, leading to tumor-infiltrating lymphocyte infiltration and upregulation of programmed cell death ligand 1 (PD-L1), indicating the significant response of SMARCA4-UT to anti-PD-1 immunotherapy.